PBYI
Puma Biotechnology, Inc.
9.60$
-0.1%
vs. previous close
Closing price · As of: Sep 21, 2026
Statements
Balance Sheet
All figures as a percentage of total assets in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 91.8% | 93.2% | 93.5% | 64.3% | 78.3% | 70.8% | 59.8% | 61.8% | 60.5% | 67.8% | 69.2% | 75.2% | |
| 23.7% | 13.2% | 76.9% | 49.4% | 41.8% | 25.6% | 34.9% | 27.9% | 34.3% | 36.7% | 32.4% | 13.7% | |
| 23.7% | 13.2% | 76.9% | 49.4% | 41.8% | 47.5% | 38.2% | 36.2% | 36.5% | 41.6% | 47.3% | 45.1% | |
| 1.1% | – | – | 5.8% | 8.5% | 12.3% | 10.5% | 14.4% | 19.0% | 21.0% | 15.0% | 24.8% | |
| 63.2% | 0.0% | 0.0% | 1.2% | 1.0% | 1.3% | 1.4% | 3.1% | 2.0% | 3.1% | 4.1% | 2.5% | |
| 1.3% | 1.0% | 2.0% | 2.7% | 1.5% | 1.4% | 1.0% | 7.0% | 0.5% | – | – | – | |
| 0.0% | 0.0% | 0.0% | 0.0% | – | – | – | – | – | – | – | – | |
| 0.0% | 0.0% | 0.0% | 29.2% | 17.1% | 17.2% | 30.4% | 29.2% | 31.8% | 26.4% | 24.0% | 19.1% | |
| 28.1% | 14.1% | 17.0% | 67.8% | 86.8% | 92.6% | 102.4% | 101.1% | 90.3% | 76.8% | 56.8% | 39.7% | |
| 27.3% | 13.5% | 14.8% | 35.2% | 25.9% | 38.7% | 46.8% | 48.4% | 34.9% | 43.1% | 45.1% | 37.6% | |
| – | – | – | 29.3% | – | 1.1% | 7.1% | 1.6% | 1.9% | 16.8% | 23.8% | 11.0% | |
| 9.2% | 7.4% | 7.9% | 16.7% | 8.0% | 8.2% | 4.9% | 4.9% | 2.9% | 3.0% | 2.6% | 2.3% | |
| 0.0% | 0.0% | 0.0% | 29.3% | 58.6% | 40.4% | 34.4% | 42.9% | 44.3% | 28.5% | 10.2% | – | |
| 71.9% | 85.9% | 83.0% | 32.2% | 13.2% | 7.4% | -2.4% | -1.1% | 9.7% | 23.2% | 43.2% | 60.3% | |
| -172.8% | -217.0% | -315.1% | -657.6% | -463.9% | -543.9% | -547.7% | -603.2% | -615.5% | -583.5% | -616.4% | -593.5% | |
| 18.4% | 13.4% | 13.2% | 22.5% | 14.6% | 16.5% | 16.2% | 17.9% | 20.2% | 20.6% | 23.0% | 23.4% |
Data as of: September 21, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.